UCB SA (OTCMKTS:UCBJY) Short Interest Update

UCB SA (OTCMKTS:UCBJY) was the target of a significant drop in short interest in the month of November. As of November 15th, there was short interest totalling 800 shares, a drop of 73.3% from the October 31st total of 3,000 shares. Based on an average trading volume of 58,500 shares, the days-to-cover ratio is currently 0.0 days.

UCB Stock Up 2.3 %

UCBJY stock traded up $2.17 during midday trading on Thursday, hitting $97.55. The company’s stock had a trading volume of 11,660 shares, compared to its average volume of 18,285. The company has a current ratio of 1.19, a quick ratio of 0.78 and a debt-to-equity ratio of 0.33. UCB has a 12 month low of $36.70 and a 12 month high of $99.40. The company has a 50 day moving average of $93.71 and a two-hundred day moving average of $84.13.

About UCB

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.